Abstract

Testing for polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene is still a standard part of thrombophilia testing in many laboratories. However, it is clear that these polymorphisms are not risk factors for arterial or venous thrombosis and therefore should not be part of thrombophilia testing. Eliminating MTHFR from thrombophilia testing will reduce patient concerns and health care costs.

Details

Title
A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing
Author
Deloughery, Thomas G 1   VIAFID ORCID Logo  ; Hunt, Beverley J 2   VIAFID ORCID Logo  ; Barnes, Geoffrey D 3   VIAFID ORCID Logo  ; Connors, Jean M 4   VIAFID ORCID Logo 

1  Division of Hematology/Medical Oncology, Knight Cancer Center, Oregon Health & Science University, Portland, Oregon, USA 
2  Kings Healthcare Partners, London, UK 
3  Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA 
4  Hematology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA 
Section
FORUM
Publication year
2022
Publication date
May 2022
Publisher
Elsevier Limited
e-ISSN
24750379
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1002/rth2.12739
ProQuest document ID
2681652406
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.